Raphael Rubin is a notable inventor based in Penn Valley, PA (US). He has made significant contributions to the field of biotechnology, particularly in the modulation of apoptosis. With a total of five patents to his name, Rubin's work has implications for cell biology and therapeutic applications.

Latest Patents

Rubin's latest patents include compositions and methods for modulating apoptosis, specifically focusing on the AAC-11 polypeptide and the DNA (RNA) encoding it. His patents detail methods for producing the AAC-11 polypeptide through recombinant techniques. Additionally, he has developed methods for using the AAC-11 polynucleotides and/or polypeptides to inhibit apoptosis in cells. His work also encompasses methods of using agonists or antagonists to the AAC-11 polypeptides to either inhibit or induce apoptosis in cells. Another significant patent involves a method of inhibiting the proliferation and causing the differentiation of cells using IGF-1 receptor antisense oligonucleotides. This method includes contacting undifferentiated cells with an effective amount of an antisense oligonucleotide that is complementary to a region of the IGF-1 receptor RNA.

Career Highlights

Raphael Rubin is affiliated with Thomas Jefferson University, where he continues to advance his research and innovations. His work has garnered attention for its potential applications in medical therapies and understanding cellular processes.

Collaborations

Some of his notable coworkers include Renato L Baserga and Christian Sell, who have contributed to his research endeavors.

Conclusion

Raphael Rubin's innovative work in the field of biotechnology, particularly in apoptosis modulation, showcases his significant contributions to science and medicine. His patents reflect a commitment to advancing our understanding of cellular mechanisms and developing potential therapeutic strategies.

Profile summary based on public USPTO records.

Please report any incorrect information to [email protected]